natgillin/translations-raw huggingface dataset:
The compound for use according to claim 13, wherein the neurodegenerative disease is Alzheimer type dementia or Down's syndrome. 
Spoj za uporabu prema zahtjevu 13, naznačen time da neurodegenerativna bolest je demencija Alzheimerovog tipa ili Downov sindrom.
A device comprising the sensor (1) as defined in claim 8, and an electronic instrument (14) for receiving, collecting, storing, processing and/or transmitting data from the sensor. A garment comprising the device of claim 12. 
Uređaj naznačen time da sadrži senzor kao što je definirano u bilo kojem od zahtjeva 10-11 i elektronski instrument (7) primanje, skupljanje, skladištenje, obradu i / ili prenošenje podataka iz navedenog senzora.
The method of claim 14, wherein the physiological signal is an ECG signal. 
Postupak u skladu s patentnim zahtjevom 14, naznačen time da je fiziološki signal EKG signal.
A chimeric antibody comprising a variable domain which specifically binds to ABCB5 and a constant domain, wherein the variable domain and the constant domain are from different species. 
Pripravak prema zahtjevu 1 ili uporaba prema zahtjevu 2, naznačen time da anti-ABCB5 protutijelo ili njegov fragment koji veže antigen je kimerno protutijelo koje sadrži varijabilnu domenu koja se specifično veže na ABCB5 i konstantnu domenu, pri čemu su varijabilna domena i konstantna domena od različitih vrsta.
The immunoglobulin single variable or the TNFR1 antagonist according to claim 7, wherein said respiratory disease is selected from: lung inflammation, COPD, Asthma, Pneumonia, cystic fibrosis interstitial lung disease, allergy, pulmonary inflammation. 
Antagonist TNFR1 u skladu s patentnim zahtjevom 9, naznačen time što se navedenu bolest dišnog sustava se bira između: upale pluća, COPD, astme, pneumonije, cistične fibroze, intersticijske bolesti pluća, alergije, plućne upale.
A topical composition for use in a method of treating rosacea, said topical composition comprising: 
Topička kompozicija za uporabu u liječenju rosaceom induciranog crvenila, navedena kompozicija obuhvaća:
A pharmaceutical suspension comprising a surfactant and nano-sized cocrystals of at least one active ingredient and at least one dicarboxylic acid. 
Farmaceutska suspenzija koja sadrži surfaktant i kokristale nano-veličine najmanje jednog aktivnog sastojka i najmanje jednu dikarboksilnu kiselinu.
The pharmaceutical suspension according to claim 1, wherein said active ingredient is a poorly water-soluble drug. 
Farmaceutska suspenzija prema zahtjevu 1, naznačena time da je navedeni aktivni sastojak lijek slabo topiv u vodi.
The pharmaceutical suspension according to claim 3, wherein the benzimidazole based anthelmintic is selected from the list consisting of albendazole, mebendazole, thiabendazole, fenbendazole, febantel, oxfendazole, triclabendazole and flubendazole; in particular flubendazole. 
Farmaceutska suspenzija prema zahtjevu 3, naznačena time da se anthelminik baziran na benzimidazolu bira iz popisa koji se sastoji od albendazola, mebendazola, tiabendazola, fenbendazola, febantela, oksfendazola, triclabendazola i flubendazola; posebno flubenzazol.
The pharmaceutical suspension according to anyone of claims 1 to 6, comprising nano-sized cocrystals of flubendazole and adipic acid. 
Farmaceutska suspenzija prema bilo kojem od zahtjeva 1 do 6, naznačena time da sadrži kokristale nano-veličine flubendazola i adipinske kiseline.
The pharmaceutical suspension for use according to claim 11; wherein the subject is selected from the list comprising humans, pigs, poultry, cattle, sheep; in particular pigs and poultry. 
Farmaceutska suspenzija za uporabu prema zahtjevu 11, naznačena time da je subjekt izabran s popisa koji obuhvaća ljude, svinje, perad, goveda, ovce; posebno svinje i perad.
dispersing at least one active ingredient, at least one dicarboxylic acid, and a surfactant in water, and milling said dispersion. 
dispergiranje najmanje jednog aktivnog sastojka, najmanje jedne dikarboksilne kiseline, i surfaktanta u vodi, i mljevenje navedene disperzije.
dispersing at least one active ingredient, at least one dicarboxylic acid, and a surfactant in water, milling said dispersion, and drying the pharmaceutical suspension. 
dispergiranje najmanje jednog aktivnog sastojka, najmanje jedne dikarboksilne kiseline, i surfaktanta u vodi, mljevenje navedene disperzije, i sušenje farmaceutske suspenzije.
A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt of claim 1, and at least one pharmaceutically acceptable carrier. 
Farmaceutski sastav koji se sastoji iz spoja ili farmaceutski prihvatljive soli iz patentnog zahtjeva 1 i najmanje jednog farmaceutski prihvatljivog nosača.
The pharmaceutical composition of claim 4, wherein said additional therapeutic agent is a NS5B polymerase inhibitor. 
Farmaceutski sastav patentnog zahtjeva 4, gdje je navedeni terapeutski agens inhibitor NS5B polimeraze.
The pharmaceutical composition according to claim 3, further comprising a nucleotide inhibitor of NS5B polymerase. 
Farmaceutski sastav prema patentnom zahtjevu 3, dalje sadrži nukleotidni inhibitor NS5B polimeraze.
A pharmaceutical composition comprising the compound of claim 2 and an inhibitor of NS5B polymerase. 
Farmaceutski sastav koji se sastoji iz spoja iz patentnog zahtjeva 2 i inhibitora NS5B polimeraze.
The pharmaceutical composition of claim 8 wherein the inhibitor of NS5B polymerase is a nucleotide inhibitor. 
Farmaceutski sastav patentnog zahtjeva 8, gdje je inhibitor NS5B polimeraze nukleotidni inhibitor.
characterized in that the RFID card comprises an active transmit circuit (2130) coupled between the smartcard controller (330) and the transmit antenna (1752) that in operation forms a signal that mimics the at least one of the frequency sideband and wherein the signal drives the transmit antenna (1752). 
aktivni prijenosni krug (2130) spojen između kontrolora pametne kartice (330) i antene za odašiljanje (1752) koji je u radu stvara signal koji oponaša barem jednu od frekvencija bočnog pojasa i pri čemu signal pobuđuje antenu za odašiljanje (1752).
Nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof for use in the treatment and/or the prevention of alcoholic or non-alcoholic steatohepatitis. 
Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, naznačene time, da se upotrebljavaju za liječenje i/ili prevenciju alkoholnog ili nealkoholnog steatohepatitisa.
Nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof for use according to claim 1, characterized in that nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof is/are formulated for oral, parenteral, subcutaneous, intravenous, intramuscular, nasal, topical or rectal administration. 
Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, prema zahtjevu 1, naznačene time, da su nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, formulirane za oralnu, parenteralnu, subkutanu, intravenoznu, intramuskularnu, nazalnu, topikalnu ili rektalnu primjenu.
Nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof for use according to claims 1 or 2, characterized in that nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof is/are to be administered to a patient in an amount of 25 mg to 5 g, preferably 100 mg to 2,5 g, in particular 800 mg to 1,5 g per day. 
Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, prema zahtjevima 1 ili 2, naznačene time, da se nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, primjenjuju na pacijentu u dnevnoj količini od 25 mg do 5 g, poželjno od 100 mg do 2,5 g, posebno od 800 mg do 1,5 g.
Nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof for use in the treatment and/or the prevention of autoimmune hepatitis. 
Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, naznačene time, da se upotrebljavaju za liječenje i/ili prevenciju alkoholnog ili nealkoholnog steatohepatitisa.
Nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof for use in the treatment and/or the prevention of autoimmune hepatitis according to claim 1, characterized in that nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof is formulated for oral, parenteral, subcutaneous, intravenous, intramuscular, nasal, topical or rectal administration. 
Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, prema zahtjevu 1, naznačene time, da su nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, formulirane za oralnu, parenteralnu, subkutanu, intravenoznu, intramuskularnu, nazalnu, topikalnu ili rektalnu primjenu.
Nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof for use in the treatment and/or the prevention of autoimmune hepatitis according to claims 1 or 2, characterized in that nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof is to be administered to a patient in an amount of 25 mg to 5 g, preferably 100 mg to 2,5 g, in particular 800 mg to 1,5 g per day. 
Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, prema zahtjevima 1 ili 2, naznačene time, da se nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, primjenjuju na pacijentu u dnevnoj količini od 25 mg do 5 g, poželjno od 100 mg do 2,5 g, posebno od 800 mg do 1,5 g.
represents an aryl group, a heteroaryl group (said aryl or heteroaryl group may be substituted by 1-3 substituent groups selected from the group consisting of a halogen atom, a -2-C1-6 alkyl group, and a C1-6 alkoxy group (said C1-6 alkyl group or C1-6 alkoxy group may be substituted by 1-3 substituent groups selected from the group consisting of a halogen atom and a hydroxy group)), a 1,3-benzodioxolanyl group, an indolyl group, a morpholyl group, a hydroxy group, a C1-6 alkyl group (said C1-6 alkyl group may be substituted by 1-2 hydroxy groups), an amino group, a mono-C1-6 alkylamino group, a di-C1-6 alkylamino group, a C1-6 alkoxy group, a C1-6 alkylsulfonyloxy group, a pyridonyl group, or a pyrimidinonyl group or a pharmaceutically acceptable salt thereof. 
predstavlja aril skupinu, heteroaril skupinu (navedena aril ili heteroaril skupina mogu biti supstituirane s 1-3 supstitucijskih skupina odabranih iz skupine koja sadrži atom halogena, -2-C1-6 alkil skupinu, te C1-6 alkoksi skupinu (navedena C1-6 alkil skupina ili C1-6 alkoksi skupina mogu biti supstituirane s 1-3 supstitucijskih skupina odabranih iz skupine koja sadrži atom halogena i hidroksi skupinu)), 1,3-benzodioksolanil skupinu, indolil skupinu, morfolil skupinu, hidroksi skupinu, C1-6 alkil skupinu (navedena C1-6 alkil skupina može biti supstituirana s 1-2 hidroksi skupine), amino skupinu, mono-C1-6 alkilamino skupinu, di-C1-6 alkilamino skupinu, C1-6 alkoksi skupinu, C1-6 alkilsulfoniloksi skupinu, piridonil skupinu, ili pirimidinonil skupinu ili njihova farmaceutski prihvatljiva sol.
The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein R2 is a phenyl group, a pyridyl group, a pyridazinyl group or a pyrimidyl group (said phenyl group, pyridyl group or pyrimidyl group may be substituted by 1-3 halogen atoms or methoxy groups), a pyridonyl group, or a pyrimidinonyl group. 
Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 4, naznačen time da R2 je fenil skupina, piridil skupina, piridazinil skupina ili pirimidil skupina (navedena fenil skupina, piridil skupina ili pirimidil skupina mogu biti supstituirane s 1-3 atoma halogena ili metoksi skupinama), piridonil skupina, ili pirimidinonil skupina.
The compound or pharmaceutically acceptable salt thereof according to claim 5, wherein R2 is a phenyl group or a pyridyl group (said phenyl group or pyridyl group may be substituted by 1-3 methoxy groups.) 
Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 5, naznačen time da R2 je fenil skupina ili piridil skupina (navedena fenil skupina ili piridil skupina mogu biti supstituirane s 1-3 metoksi skupine.)
An additive composition for scavenging hydrogen sulfide in hydrocarbons or hydrocarbon streams, wherein the additive composition consists of glyoxal and a polymer compound, which polymer compound is made from propylene oxide. 
Sastav aditiva za prikupljanje sumporovodika u ugljikovodicima ili strujama ugljikovodika, naznačen time što se sastav aditiva sastoji od glioksala i spoja polimera, koji spoj polimera je napravljen od propilen oksida.
An additive composition as claimed in claim 1, wherein glyoxal and the polymer compound are taken in an amount varying between 99 parts of glyoxal to 0.1 part of polymer compound and 0.1 part of glyoxal to 99 parts of polymer compound. 
Sastav aditiva temeljem zahtjeva 1, naznačen time što su glioksal i spoj polimera uzeti u količini koja varira između 99 dijelova glioksala naspram 0.1 dijela spoja polimera i 0.1 dijelova glioksala do 99 dijelova spoja polimera.
An additive composition as claimed in claim 1 or 2, wherein the polymer compound varies up to about 25% by weight, preferably up to about 10% by weight or up to about 5% by weight of the additive composition. 
Sastav aditiva temeljem zahtjeva 1 ili 2, naznačen time što spoj polimera varira do oko 25% težinski, poželjno do oko 10% težinski ili do oko 5% težinski sastava aditiva.
An additive composition as claimed in any one of claims 1 to 3, wherein the propylene oxide is polypropylene glycol. 
Sastav aditiva temeljem bilo kojeg od zahtjeva 1 do 3, naznačen time što je propilen oksid polipropilen glikol.
An additive composition as claimed in any one of claims 1 to 4, wherein the polypropylene glycol has a molecular weight of about 200 to about 800 daltons. 
Sastav aditiva temeljem bilo kojeg od zahtjeva 1 do 4, naznačen time što polipropilen glikol ima molekularnu težinu od oko 200 do oko 800 daltona.
Use of an additive composition as claimed in claim 7 or 8, wherein the polymer compound varies up to about 25% by weight, preferably up to about 10% by weight or up to about 5% by weight of the additive composition. 
Upotreba sastava aditiva temeljem zahtjeva 7 ili 8, naznačena time što spoj polimera varira do oko 25% težinski, poželjno do oko 10% težinski ili do oko 5% težinski sastava aditiva.
Use of an additive composition as claimed in any one of claims 7 to 11, wherein the hydrocarbon streams include crude oil, fuel oil, sour gas, and asphalts and refined products contained in storage tanks, vessels, pipelines. 
Upotreba sastava aditiva temeljem bilo kojeg od zahtjeva 7 do 11, naznačena time što struje ugljikovodika uključuju sirovu naftu, lož ulje, plinove koji sadrže sumporovodik, i asfalte i rafinirane proizvode koji se drže u spremnicima, tankovima, cjevovodima.
A method as claimed in claim 14 or 15, wherein the polymer compound varies up to about 25% by weight, preferably up to about 10% by weight or up to about 5% by weight of the composition. 
Metoda temeljem zahtjeva 14 ili 15, naznačena time što spoj polimera varira do oko 25% težinski, poželjno do oko 10% težinski ili do oko 5% težinski sastava aditiva.
A method as claimed in any one of claims 14 to 16, wherein the propylene oxide is polypropylene glycol. 
Metoda temeljem bilo kojeg od zahtjeva 14 do 16, naznačena time što je propilen oksid polipropilen glikol.
A method as claimed in any one of claims 14 to 17, wherein the polypropylene glycol has a molecular weight of about 200 to about 800 daltons. 
Metoda temeljem bilo kojeg od zahtjeva 14 do 17, naznačena time što polipropilen glikol ima molekularnu težinu od oko 200 do oko 800 daltona.
A method as claimed in any one of claims 14 to 18, wherein the hydrocarbon streams include crude oil, fuel oil, sour gas, and asphalts and refined products contained in storage tanks, vessels, pipelines. 
Metoda temeljem bilo kojeg od zahtjeva 14 do 18, naznačena time što struje ugljikovodika uključuju sirovu naftu, lož ulje, plinove koji sadrže sumporovodik, i asfalte i rafinirane proizvode koji se drže u spremnicima, tankovima, cjevovodima.
A method as claimed in any one of claims 14 to 20, wherein the additive composition is added in an amount varying from about 1 to about 4000 ppm by weight of hydrocarbon or hydrocarbon stream. 
Metoda temeljem bilo kojeg od zahtjeva 14 do 20, naznačena time što se sastav aditiva dodaje u količini koja varira od oko 1 do oko 4000 ppm težinski ugljikovodika ili struje ugljikovodika.
A method as claimed in any one of claims 14 to 21, wherein the additive composition is injected in flow lines in case of development stage of a field or in small producing fields. 
Metoda temeljem bilo kojeg od zahtjeva 14 do 21, naznačena time što se sastav aditiva injektira u linije protoka u slučaju razvojne faze polja ili kod polja s malom proizvodnjom.
A method as claimed in any one of claims 14 to 22, wherein gas containing hydrogen sulfide is passed through an absorption tower wherein the additive composition has been injected in case of large production facilities. 
Metoda temeljem bilo kojeg od zahtjeva 14 do 22, naznačena time što se plin koji sadrži sumporovodik provodi kroz apsorpcijski toranj pri čemu je sastav aditiva bio injektiran u slučaju postrojenja s velikom produkcijom.
A method as claimed in any one of claims 14 to 23, wherein the additive composition is added to crude oil when it is passing through a desalter or is being treated with wash water in a crude oil processing system. 
Metoda temeljem bilo kojeg od zahtjeva 14 do 23, naznačena time što se sastav aditiva dodaje sirovoj nafti kad ona prolazi kroz odsoljivač ili kad je se tretira s vodom za ispiranje u sustavu obrade sirove nafte.
Z is a bond, -CH2- or -O-; or a pharmaceutically suitable acid addition salt thereof. 
Z je veza, -CH2- ili -O-; ili njegova farmaceutski prikladna kiselinska adicijska sol.
cleaving off the N-protecting group from compounds of formula to a compound of formula wherein PG is a N-protecting group selected from -C(O)O-tert-butyl and the other definitions are as described in claim 1, and, if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts. 
[image] na spoj sljedećih formula: [image] pri čemu PG je N-zaštitna skupina odabrana od -C(O)O-tert-butila, a ostale definicije su prema opisu u zahtjevu 1, te ako je potrebno, pretvaranje dobivenih spojeva u farmaceutski prikladne kiselinske adicijske soli.
A pharmaceutical composition comprising a compound according to any one of claims 1-14 and a pharmaceutical acceptable carrier and/or adjuvant. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj prema bilo kojem od zahtjeva 1 do 14 i farmaceutski prikladan nosač i/ili pomoćno sredstvo.
A pharmaceutical composition comprising a compound according to any one of claims 1 -9 and a pharmaceutical acceptable carrier and/or adjuvant for use in the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders. 
Farmaceutski sastav koji obuhvaća spoj prema bilo kojem od zahtjeva 1 do 9, te farmaceutski prikladan nosač i/ili pomoćno sredstvo, naznačen time, da se upotrebljava u liječenju depresije, anksioznih poremećaja, bipolarnog poremećaja, poremećaja s pomanjkanjem pažnje i hiperaktivnosti (ADHD), poremećaja povezanih sa stresom, psihotičkih poremećaja, shizofrenije, neuroloških bolesti, Parkinsonove bolesti, neurodegenerativnih poremećaja, Alzheimerove bolesti, epilepsije, migrene, hipertenzije, zlouporabe droga, metaboličkih poremećaja, poremećaja hranjenja, dijabetesa, dijabetskih komplikacija, pretilosti, dislipidemije, poremećaja potrošnje i izjednačavanja energije, poremećaja i zastoja homeostaze tjelesne temperature, poremećaja spavanja i cirkadijanog ritma, te kardiovaskularnih poremećaja.
Compounds according to any one of claims 1 -9 for use as therapeutic active substances in the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders. 
Spojevi prema bilo kojem od zahtjeva 1 do 9, naznačeni time, da se upotrebljavaju kao terapeutski djelotvorne tvari za liječenje depresije, anksioznih poremećaja, bipolarnog poremećaja, poremećaja s pomanjkanjem pažnje i hiperaktivnosti (ADHD), poremećaja povezanih sa stresom, psihotičkih poremećaja, shizofrenije, neuroloških bolesti, Parkinsonove bolesti, neurodegenerativnih poremećaja, Alzheimerove bolesti, epilepsije, migrene, hipertenzije, zlouporabe droga, metaboličkih poremećaja, poremećaja hranjenja, dijabetesa, dijabetskih komplikacija, pretilosti, dislipidemije, poremećaja potrošnje i izjednačavanja energije, poremećaja i zastoja homeostaze tjelesne temperature, poremećaja spavanja i cirkadijanog ritma, te kardiovaskularnih poremećaja.
The use of a compound according to any one of claims 1 -9 for the preparation of medicaments for the therapeutic and/or prophylactic treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders. 
Uporaba spoja prema bilo kojem od zahtjeva 1 do 9, naznačena time, da je za proizvodnju lijekova za terapeutsko i/ili profilaktičko liječenje depresije, anksioznih poremećaja, bipolarnog poremećaja, poremećaja s pomanjkanjem pažnje i hiperaktivnosti (ADHD), poremećaja povezanih sa stresom, psihotičkih poremećaja, shizofrenije, neuroloških bolesti, Parkinsonove bolesti, neurodegenerativnih poremećaja, Alzheimerove bolesti, epilepsije, migrene, hipertenzije, zlouporabe droga, metaboličkih poremećaja, poremećaja hranjenja, dijabetesa, dijabetskih komplikacija, pretilosti, dislipidemije, poremećaja potrošnje i izjednačavanja energije, poremećaja i zastoja homeostaze tjelesne temperature, poremećaja spavanja i cirkadijanog ritma, te kardiovaskularnih poremećaja.
Nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof for use in the treatment and/or the prevention of hepatocellular carcinoma and cholangiocarcinoma. 
Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, naznačene time, da se upotrebljavaju za liječenje i/ili prevenciju hepatocelularnog karcinoma i kolangiokarcinoma.